title: Impact of hyperthermic intraperitoneal chemotherapy on Hsp27 protein expression in serum of patients with peritoneal carcinomatosis.
abstract: Despite the strong rationale for combining cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis, thermotolerance and chemoresistance might result from heat shock protein overexpression. The aim of the present study was thus to determine whether the heat shock protein 27 (Hsp27), a potential factor in resistance to treatment, could have a higher level in serum from patients under this combined therapy. Patients receiving CRS plus HIPEC for peritoneal carcinomatosis (group 1), patients with cancer or a history of cancer undergoing abdominal surgery (group 2), and patients without malignancies undergoing abdominal surgery (group 3) were included. Hsp27 serum levels were determined before and at different times following CRS and HIPEC using enzyme-linked immunosorbent assay. In group 1 (n = 25), the high Hsp27 levels, observed at the end of surgery compared with before (p < 0.0001), decreased during HIPEC, but remained significantly higher than before surgery (p < 0.0005). In groups 2 (n = 11) and 3 (n = 15), surgery did not significantly increase Hsp27 levels. A targeted molecular strategy, inhibiting Hsp27 expression in tumor tissue, could significantly reduce resistance to the combined CRS plus HIPEC treatment. This approach should be further assessed in a clinical phase I trial.
authors.affiliation: EMR3738, Faculté de Médecine Lyon-Sud, Université Lyon 1, BP12 69921, Oullins Cedex, France.
authors.forename: Vahan
authors.initials: V
authors.lastname: Kepenekian
authors.forename: Marie-Thérèse
authors.initials: MT
authors.lastname: Aloy
authors.forename: Nicolas
authors.initials: N
authors.lastname: Magné
authors.forename: Guillaume
authors.initials: G
authors.lastname: Passot
authors.forename: Emma
authors.initials: E
authors.lastname: Armandy
authors.forename: Evelyne
authors.initials: E
authors.lastname: Decullier
authors.forename: Annie
authors.initials: A
authors.lastname: Sayag-Beaujard
authors.forename: François-Noël
authors.initials: FN
authors.lastname: Gilly
authors.forename: Olivier
authors.initials: O
authors.lastname: Glehen
authors.forename: Claire
authors.initials: C
authors.lastname: Rodriguez-Lafrasse
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D055551:HSP27 Heat-Shock Proteins / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000627:therapeutic use; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D000970:Antineoplastic Agents; D055551:HSP27 Heat-Shock Proteins; D016685:Mitomycin; D002097:C-Reactive Protein; D002945:Cisplatin